Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era

Cancer - Tập 103 Số 4 - Trang 821-829 - 2005
Bengt Nilsson1,2, Per Bümming1, Jeanne M. Meis‐Kindblom3, Anders Odén3, Aydin Dortok4,5, Bengt Gustavsson4,6, Katarzyna Sablinska4,7, Lars‐Gunnar Kindblom3,2
1Department of Surgery, The Lundberg Laboratory for Cancer Research, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden
2Drs. Lars-Gunnar Kindblom and Bengt Nilsson have acted as members of a Novartis Glivec® Advisory Board.
3Department of Pathology, The Lundberg Laboratory for Cancer Research, Sahlgrenska Academy at the University of Göteborg, Göteborg, Sweden
4Drs. Aydin Dortok, Bengt Gustavsson, and Katarzyna Sablinska are employed by Novartis Pharma.
5Novartis Oncology, Florham Park, New Jersey
6Novartis Oncology, Stockholm, Sweden
7Novartis Oncology, Basel, Switzerland

Tóm tắt

AbstractBACKGROUNDRecent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria and have led to the development of molecularly targeted drug therapy. New treatment options mandate more accurate information regarding the incidence, prevalence, clinical behavior, and prognostic factors of GIST.METHODSAll patients (n = 1460) who potentially had GIST diagnosed from 1983 to 2000 in western Sweden (population, 1.3–1.6 million) were reviewed, and 288 patients with primary GIST were identified. The incidence and prevalence of GIST were determined, and predictive prognostic factors, including current risk‐group stratifications, were analyzed statistically.RESULTSNinety percent of GISTs were detected clinically due to symptoms (69%) or were incidental findings at surgery (21%); the remaining 10% of GISTs were found at autopsy. Forty‐four percent of symptomatic, clinically detected GISTs were categorized as high risk (29%) or overtly malignant (15%), with tumor‐related deaths occurring in 63% of patients and 83% of patients, respectively (estimated median survival, of 40 months and 16 months, respectively). Tumor‐related deaths occurred in only 2 of 170 of patients (1.2%) with very‐low‐risk, low‐risk, or intermediate‐risk tumors. The annual incidence of GIST was 14.5 per million. The prevalence of all GIST risk groups was 129 per million (31 per million for the high‐risk group and the overtly malignant group).CONCLUSIONSGIST has been under recognized: Its incidence, prevalence, and clinical aggressiveness also have been underestimated. Currently existing risk‐group stratification systems based on tumor size and mitotic rate delineate GIST patients who have a poor prognosis. Prognostication in patients with GIST can be refined using a proposed risk score based solely on tumor size and proliferative index. Cancer 2005. © 2005 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.1053/hupa.2002.123545

10.1097/00000658-200001000-00008

Kindblom LG, 1998, Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal, Am J Pathol., 152, 1259

10.1126/science.279.5350.577

10.1016/S0002-9440(10)64946-2

Rubin BP, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res., 61, 8118

10.1016/S0002-9440(10)61103-0

10.1182/blood.V96.3.925

10.1038/sj.onc.1204704

10.1200/JCO.2002.20.6.1692

10.1056/NEJM200104053441404

10.1056/NEJMoa020461

10.1016/S0140-6736(01)06535-7

10.1016/S1470-2045(02)00899-9

Breslow NE, 1987, 131

10.1053/hupa.2002.124122

10.1007/s004280000338

10.1002/1097-0142(19950101)75:1 <154::AID-CNCR2820751305>3.0.CO;2-Z

10.1053/hupa.2002.124123

10.1097/00000478-199704000-00006

Suster S, 1996, Gastrointestinal stromal tumors, Semin Diagn Pathol., 13, 297

10.1177/106689690000800208

10.1016/S0046-8177(98)90447-6

10.1097/00000478-199501000-00009

Emory TS, 1997, Ki‐67 (MIB‐1) immunohistochemistry as a prognostic factor in gastrointestinal smooth‐muscle tumors, J Surg Pathol., 239

Thông tin
Thông tin xuất bản

Cancer

Tập 103 Số 4

821-829

Thông tin tác giả